+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
FEMALE
ID07564141

Evaluation of Rina-S With or Without Bevacizumab Compared to Platinum-Based Chemotherapy With or Without Bevacizumab as Second-Line Treatment in Women With Recurrent Platinum-Sensitive Ovarian Cancer

Led by Genmab · Updated on 2026-11-04

688

Participants Needed

12

Research Sites

100 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness of Rina-S, alone or combined with bevacizumab, compared to an investigators choice of platinum-based chemotherapy with or without bevacizumab. This Phase 3 study involves up to about 688 female participants worldwide with recurrent platinum-sensitive ovarian cancer who have had prior platinum-based chemotherapy. The study aims to assess how well these treatments work as second-line options. Participants will be randomly assigned to one of two groups one receiving Rina-S with or without bevacizumab every three weeks, and the other receiving investigators choice chemotherapy regimens carboplatin plus gemcitabine, paclitaxel, or pegylated liposomal doxorubicin, also with or without bevacizumab. Treatment cycles last three or four weeks depending on the medication. Participants may continue receiving treatment as long as their cancer does not worsen and they tolerate the therapy. During each treatment cycle, participants will attend one to three clinic visits for tests such as blood draws, heart activity recordings, and imaging to monitor safety and response. The main outcome measured is progression-free survival over approximately three years, with additional outcomes including overall survival and quality of life assessments up to five years. The total study duration, including screening, treatment, and follow-up, varies for each participant.

CONDITIONS

Brief Title

Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer

Research Team

G

Genmab Trial Information

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here